2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges

New data on drug pricing for 2025 highlights a clear shift in how pharmaceutical manufacturers manage market access. Examining eight top companies, including Sanofi and Bristol Myers Squibb, we see that list prices continue to rise slowly. However, the rebates, discounts, and fees paid to intermediaries are now impacting net revenues in a way that suggests the long-standing gross-to-net bubble is finally starting to deflate.

Manufacturers now retain less than half of their list prices on average. Sanofi provides an excellent case study in this change. While their sales grew by 76% between 2020 and 2025, their total rebate payments increased by only 10%. This divergence indicates that the industry is moving away from the high-list-price and high-rebate model that dominated the previous two decades. Strategies are changing as companies launch new products with lower list prices and smaller gross-to-net gaps.

This transition points toward the emergence of a Net Pricing Drug Channel. Structural pressure from legislative reforms and shifting competitive dynamics is forcing a recalculation of how these companies approach formulary access. While the rebate system is not gone, the era of runaway growth in gross-to-net reductions appears to be slowing significantly.

The findings are consistent across most of the eight manufacturers reviewed. Net prices for brand-name drugs declined at nearly every company during 2025, even as inflation persisted. As manufacturers adjust their tactics to survive in this new environment, the broader drug channel will likely continue to evolve. Investors and industry watchers should expect 2026 data to provide further evidence of this fundamental shift in pricing strategy.